Welgene Biotech Co.,Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 08, 2022
Share
Welgene Biotech Co.,Ltd. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was TWD 105.46 million compared to TWD 75.51 million a year ago. Net income was TWD 12.49 million compared to TWD 5.77 million a year ago. Basic earnings per share from continuing operations was TWD 0.54 compared to TWD 0.25 a year ago. Diluted earnings per share from continuing operations was TWD 0.54 compared to TWD 0.25 a year ago.
For the six months, sales was TWD 177.42 million compared to TWD 123.82 million a year ago. Net income was TWD 7.4 million compared to TWD 0.242 million a year ago. Basic earnings per share from continuing operations was TWD 0.32 compared to TWD 0.01 a year ago. Diluted earnings per share from continuing operations was TWD 0.32 compared to TWD 0.01 a year ago.
WELGENE BIOTECH CO., LTD. is a Taiwan-based company mainly engaged in the provision of genetic testing services and products. The company focuses on deoxyribonucleic acid (DNA) microarray, Next Generation Sequencing and real-time quantitative polymerase chain reaction (PCR) and other testing technologies, which used in school research units, hospitals and biotech companies. The Company is also engaged in the trading of medical equipment. The company mainly operates in two business segments, including Biotechnology Testing segment and Equipment Trading segment. The Company mainly operates in Taiwan market.